Cargando…
Ligand efficiency indices for drug discovery : towards an atlas-guided paradigm /
The purpose of Ligand Efficiency Indices for Drug Discovery: Towards an Atlas-Guided Paradigm is to introduce in a concise and self-contained form the concepts, ideas, applications and examples of efficiency-driven drug discovery to the biomedical community at large. The book emphasizes the use of &...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
Oxford :
Elsevier,
2013.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Ma 4500 | ||
|---|---|---|---|
| 001 | SCIDIR_ocn828743338 | ||
| 003 | OCoLC | ||
| 005 | 20231117044833.0 | ||
| 006 | m o d | ||
| 007 | cr cn||||||||| | ||
| 008 | 130207s2013 enkad ob 000 0 eng d | ||
| 040 | |a E7B |b eng |e pn |c E7B |d OCLCO |d UIU |d N$T |d OPELS |d YDXCP |d OCLCF |d UIU |d CGU |d GGVRL |d EBLCP |d UKDOC |d OCLCQ |d MERUC |d OCLCQ |d U3W |d D6H |d AU@ |d OCLCO |d MERER |d OCLCQ |d OCLCO |d OCLCA |d OCLCQ |d SFB |d S2H |d OCLCO |d OCLCQ |d OCL |d OCLCO | ||
| 019 | |a 827208182 |a 841560511 |a 1058265211 |a 1136418261 |a 1162496618 |a 1300647711 | ||
| 020 | |a 9780124046825 |q (electronic bk.) | ||
| 020 | |a 0124046827 |q (electronic bk.) | ||
| 020 | |z 9780124046351 | ||
| 020 | |z 0124046355 | ||
| 035 | |a (OCoLC)828743338 |z (OCoLC)827208182 |z (OCoLC)841560511 |z (OCoLC)1058265211 |z (OCoLC)1136418261 |z (OCoLC)1162496618 |z (OCoLC)1300647711 | ||
| 050 | 4 | |a RM301.25 |b .A23 2013eb | |
| 072 | 7 | |a MED |x 023000 |2 bisacsh | |
| 072 | 7 | |a MED |x 058170 |2 bisacsh | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 072 | 7 | |a MED |x 072000 |2 bisacsh | |
| 082 | 0 | 4 | |a 615.19 |2 23 |
| 100 | 1 | |a Abad Zapatero, Celerino. | |
| 245 | 1 | 0 | |a Ligand efficiency indices for drug discovery : |b towards an atlas-guided paradigm / |c Celerino Abad-Zapatero. |
| 260 | |a Oxford : |b Elsevier, |c 2013. | ||
| 300 | |a 1 online resource (xix, 158 pages) : |b illustrations (some color) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 504 | |a Includes bibliographical references. | ||
| 505 | 0 | |a pt. I. The elements : data, variables, concept, and the server -- pt. II. Conceptual applications of the atlasCBS : a new paradigm -- pt. III. Exploring CBS : practical examples using the atlasCBS server. | |
| 520 | |a The purpose of Ligand Efficiency Indices for Drug Discovery: Towards an Atlas-Guided Paradigm is to introduce in a concise and self-contained form the concepts, ideas, applications and examples of efficiency-driven drug discovery to the biomedical community at large. The book emphasizes the use of 'new variables' and more objective numerical methods to drive drug discovery in an encompassing way. These 'new variables' are based on Ligand Efficiency Indices (LEIs) formulated in a way that permits mapping Chemico-Biological Space (CBS) in an Atlas-like representation. It provides a practical and timely discussion of the concepts, ideas, applications and examples of efficiency-driven drug discovery. This book emphasizes the use of a graphical representation and objective numerical methods to drive drug discovery more effectively. It presents the definition of LEIs and the corresponding efficiency planes within an atlas-like environment to provide a robust graphical and numerical framework for medicinal chemists and drug-discoverers. Provides a practical and timely discussion of the concepts, ideas, applications and examples of efficiency-driven drug discoveryEmphasizes the use of 'new variables' and more objective numerical methods to drive quicker and more effective drug discoveryPresents the definition of Ligand Efficiency Indices (LEIs) and the corresponding efficiency planes as key concepts to provide a graphical and numerical framework. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Drug development. | |
| 650 | 0 | |a Structure-activity relationships (Biochemistry) | |
| 650 | 0 | |a Pharmaceutical chemistry. | |
| 650 | 0 | |a Metabolism. | |
| 650 | 0 | |a Chemistry. | |
| 650 | 0 | |a Pharmacology. | |
| 650 | 0 | |a Physical sciences. | |
| 650 | 0 | |a Life sciences. | |
| 650 | 0 | |a Carrier proteins. | |
| 650 | 0 | |a QSAR (Biochemistry) | |
| 650 | 0 | |a Ligands. | |
| 650 | 2 | |a Structure-Activity Relationship |0 (DNLM)D013329 | |
| 650 | 2 | |a Chemistry, Pharmaceutical |0 (DNLM)D002626 | |
| 650 | 2 | |a Biochemical Phenomena |0 (DNLM)D001669 | |
| 650 | 2 | |a Investigative Techniques | |
| 650 | 2 | |a Metabolism |0 (DNLM)D008660 | |
| 650 | 2 | |a Laboratory Chemicals |0 (DNLM)D019995 | |
| 650 | 2 | |a Chemistry |0 (DNLM)D002621 | |
| 650 | 2 | |a Specialty Uses of Chemicals | |
| 650 | 2 | |a Chemical Phenomena |0 (DNLM)D055598 | |
| 650 | 2 | |a Analytical, Diagnostic and Therapeutic Techniques and Equipment | |
| 650 | 2 | |a Pharmacological Phenomena |0 (DNLM)D000069437 | |
| 650 | 2 | |a Pharmacology |0 (DNLM)D010600 | |
| 650 | 2 | |a Physiological Phenomena |0 (DNLM)D010829 | |
| 650 | 2 | |a Chemical Actions and Uses | |
| 650 | 2 | |a Phenomena and Processes | |
| 650 | 2 | |a Natural Science Disciplines |0 (DNLM)D010811 | |
| 650 | 2 | |a Biological Science Disciplines |0 (DNLM)D001690 | |
| 650 | 2 | |a Disciplines and Occupations | |
| 650 | 2 | |a Chemicals and Drugs | |
| 650 | 2 | |a Carrier Proteins |0 (DNLM)D002352 | |
| 650 | 2 | |a Drug Discovery |0 (DNLM)D055808 | |
| 650 | 2 | |a Quantitative Structure-Activity Relationship |0 (DNLM)D021281 | |
| 650 | 2 | |a Ligands |0 (DNLM)D008024 | |
| 650 | 6 | |a M�edicaments |x D�eveloppement. |0 (CaQQLa)201-0306620 | |
| 650 | 6 | |a Relations structure-activit�e (Biochimie) |0 (CaQQLa)201-0028673 | |
| 650 | 6 | |a Chimie pharmaceutique. |0 (CaQQLa)201-0028674 | |
| 650 | 6 | |a M�etabolisme. |0 (CaQQLa)201-0062122 | |
| 650 | 6 | |a Chimie. |0 (CaQQLa)201-0006068 | |
| 650 | 6 | |a Pharmacologie. |0 (CaQQLa)201-0007219 | |
| 650 | 6 | |a Sciences physiques. |0 (CaQQLa)201-0039805 | |
| 650 | 6 | |a Sciences de la vie. |0 (CaQQLa)201-0078730 | |
| 650 | 6 | |a Prot�eines de liaison. |0 (CaQQLa)201-0088002 | |
| 650 | 6 | |a Relations structure-activit�e quantitatives (Biochimie) |0 (CaQQLa)201-0379113 | |
| 650 | 6 | |a Ligands. |0 (CaQQLa)201-0027688 | |
| 650 | 7 | |a metabolism (biological concept) |2 aat |0 (CStmoGRI)aat300254909 | |
| 650 | 7 | |a chemistry. |2 aat |0 (CStmoGRI)aat300054537 | |
| 650 | 7 | |a pharmacology. |2 aat |0 (CStmoGRI)aat300137970 | |
| 650 | 7 | |a physical sciences. |2 aat |0 (CStmoGRI)aat300054532 | |
| 650 | 7 | |a biological sciences. |2 aat |0 (CStmoGRI)aat300054464 | |
| 650 | 7 | |a MEDICAL |x Drug Guides. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Nursing |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Pharmacy. |2 bisacsh | |
| 650 | 7 | |a Structure-activity relationships (Biochemistry) |2 fast |0 (OCoLC)fst01135737 | |
| 650 | 7 | |a QSAR (Biochemistry) |2 fast |0 (OCoLC)fst01084801 | |
| 650 | 7 | |a Physical sciences |2 fast |0 (OCoLC)fst01062723 | |
| 650 | 7 | |a Pharmacology |2 fast |0 (OCoLC)fst01060259 | |
| 650 | 7 | |a Pharmaceutical chemistry |2 fast |0 (OCoLC)fst01060115 | |
| 650 | 7 | |a Metabolism |2 fast |0 (OCoLC)fst01017473 | |
| 650 | 7 | |a Ligands |2 fast |0 (OCoLC)fst00998466 | |
| 650 | 7 | |a Life sciences |2 fast |0 (OCoLC)fst00998323 | |
| 650 | 7 | |a Chemistry |2 fast |0 (OCoLC)fst00853344 | |
| 650 | 7 | |a Carrier proteins |2 fast |0 (OCoLC)fst00847934 | |
| 650 | 7 | |a Drug development |2 fast |0 (OCoLC)fst00898670 | |
| 776 | 0 | 8 | |i Print version: |a Abad-Zapatero, Celerino. |t Ligand Efficiency Indices for Drug Discovery : Towards an Atlas-Guided Paradigm. |d Burlington : Elsevier Science, �2013 |z 9780124046351 |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780124046351 |z Texto completo |
| 856 | 4 | 0 | |u https://sciencedirect.uam.elogim.com/science/book/9780124046351 |z Texto completo |